Oct 28, 2025 | News |
A STATEMENT FROM THE OFFICE OF THE CEO Issued by Clear Health Pass Holdings, LLC, as Authorized Tribal Agent It has come to the attention of Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium,...
Oct 13, 2025 | News |
The Centers for Medicare & Medicaid Services has issued Rampart™ DL Matrix (HCPCS Q4347), the only FDA-cleared tribally owned skin substitute in the Medicare system, on the Q4 2025 Average Sales Price file for Medicare Part B. The Q4 2025 ASP rate took effect for...
Sep 16, 2025 | News |
The Tribal Biotechnology & Health Consortium’s full sovereign submission on the CY 2026 Medicare Physician Fee Schedule has been posted publicly on Regulations.gov, the federal government’s official rulemaking record platform, under Comment ID CMS-2025-0304-13291....
Sep 12, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed its formal sovereign comment on the proposed CY 2026 Medicare Physician Fee Schedule (CMS-1832-P), continuing a coordinated, multi-docket engagement with the Centers for Medicare & Medicaid Services. The...
Sep 4, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed its formal comment on the proposed CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule (CMS-1834-P), addressing the proposed treatment of skin substitute...
Jul 28, 2025 | News |
Clear Health Pass Holdings, on behalf of the Tribal Biotechnology & Health Consortium, today announced the appointment of David Burke, MD, MA as Principal Investigator for the post-market clinical validation of Rampart™ DL Matrix (Q4347). Dr. Burke is Department...
